Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type II
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
PF-06291874
PF-06291874
PF-06291874
PF-06291874
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type II
Eligibility Criteria
Inclusion Criteria:
- Male subjects and non-childbearing potential female subjects between the ages of 18 and 70 years old.
- Body Mass Index of 18.0 to 45.4 kg/m2; and a total body weight of >50 kg
HbA1c value at the screening visit meeting once of the following criteria:
- Currently taking acceptable oral antiglycemic drug therapy within 6.5 to 9.5%
- Not currently taking any oral antiglycemic drug therapy within 7 to 10.5%
- Fasting plasma glucose concentrations<270mg/dL at the screening and run-in visit, confirmed by a single repeat, if deemed necessary.
- Subjects must be willing and able to perform self-tests of blood glucose at least 4 times per day, and maintain a diary for the duration of participation in the study; and therefore, subjects must be literate.
Exclusion Criteria:
- History of Type 1 diabetes mellitus or secondary forms of diabetes
- One or more self-reported hypoglycemic episodes of sever intensity within 3 months of screening; or 2 or more self-reported hypoglycemic episodes of severe intensity within the previous 6 months.
- History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class II-IV heart failure, or transient ischemic attach within 6 months of screening.
History or evidence of diabetic complications with significant end organ damage, such as
- Proliferative retinopathy and/or macular edema;
- Diabetic neuropathy complicated by neuropathic ulcers;
- Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure >100 mm Hg after at least a 5 minute seated rest. If the blood pressure exceeds this limit, the blood pressure may be repeated 2 more times following approximately 2 minutes of rest between measurements and the median of the 3 values should be used to determine subject eligibility;
- Male subjects with partners currently pregnant; or male subjects capable of conceiving children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
Sites / Locations
- Anaheim Clinical Trials, LLC
- Profil Institute for Clinical Research, Inc.
- Diablo Clinical Research, Inc.
- Avail Clinical Research, LLC
- SeaView Research, Inc.
- SeaView Research, Inc.
- Compass Research, LLC
- Miami Research Associates, Inc.
- MRA Clinical Research, LLC
- MRA Clinical Research
- Louisville Metabolic and Atherosclerosis Research Center
- DaVita Clinical Research
- Clinilabs, Inc.
- PRA International
- Buffalo Clinical Research Center, LLC
- High Point Clinical Trials Center, LLC
- Community Research
- Clinical Trials of Texas, Inc.
- Rainier Clinical Research Center, Inc.
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Arm Label
Treatment A- Placebo
Treatment B- PF-06291874
Treatment C- PF-06291874
Treatment D- PF-06291874
Treatment E- PF-06291874
Arm Description
Outcomes
Primary Outcome Measures
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), or Serious Adverse Events (SAEs), or Hypoglycemic Adverse Events (HAE) or Withdrawals Due to Adverse Events (AEs)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. An HAE was identified by characteristic symptoms or blood glucose levels. TEAEs are events between first dose of study drug and up to 10-14 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.
Number of Participants With Laboratory Test Abnormalities
The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.
Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Criteria of Potential Clinical Concern
Vital Signs included seated supine systolic and diastolic blood pressure (BP) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic (SBP) greater than or equal to (>=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (<) 90 mm Hg; diastolic BP (DBP) >=20 mm Hg change from baseline, diastolic <50 mm Hg; 2), pulse rate <40 or greater than (>) 120 beats per minute (bpm).
Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern
ECG criteria of potential clinical concern were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): >=140 msec; >=50% increase from baseline; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): >=300 milliseconds (msec); >=25 percent (%) increase when baseline >200 msec; or increase >=50% when baseline less than or equal to (<=)200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value >=450 - <480 msec, >=480-<500 msec, >=500 msec; increase from baseline >=30 - <60, >=60 msec.
Secondary Outcome Measures
Change From Baseline in Mean Daily Glucose
The mean daily glucose was determined from the area under the concentration (AUC) of the glucose concentrations measured at nominal times 0, 0.5, 1, 1.5, 2, 4, 6, 10, 12, 15 and 24 hours post dose. Mean daily glucose change from baseline (defined as Day 0) on Day 28.
Change From Baseline in Fasting Plasma Glucose
Fasting plasma glucose response change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Percent Change From Baseline in Triglycerides
Triglycerides percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Percent Change From Baseline in Total Cholesterol
Total cholesterol percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)
LDL-C percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)
HDL-C percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Percent Change From Baseline in Non-HDL-C
Non-HDL-C percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Percent Change From Baseline in Oxidized LDL
Oxidized LDL percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in Large LDL Particles
Large LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in Medium Small LDL Particles
Medium small LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in Small LDL Particles
Small LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in Very Small LDL Particles
Very small LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in Total LDL Particles
Total LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in LDL Size
The LDL size percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Percent Change From Baseline in Apolipoprotein B100
The Apolipoprotein B100 was calculated as the difference between total Apolipoprotein B and Apolipoprotein B48 and analyzed the percent change from baseline (defined as mean of Day 0 and Day 1) on Day 28 (mean of Days 28 and 29).
Percent Change From Baseline in Lipoprotein A
The Lipoprotein A percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (mean of Days 28 and 29).
Maximum Plasma Concentration (Cmax)
Maximum PF-06291874 plasma concentration.
Time to Reach Cmax (Tmax)
Time to maximum PF-06291874 plasma concentration.
Area Under the Concentration-Time Profile From Zero to Time Tau (AUCtau) (Where Tau=24 Hours)
Area under the PF-06291874 plasma concentration-time profile from time zero to time tau, the dosing interval, where tau=24 hours.
Minimum Plasma Concentration (Cmin)
Minimum PF-06291874 plasma concentration.
Apparent Clearance (CL/F)
Apparent oral clearance of PF-06291874.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02175121
Brief Title
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
Official Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of Pf-06291874 Given As Monotherapy To Adults With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type II
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
172 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment A- Placebo
Arm Type
Placebo Comparator
Arm Title
Treatment B- PF-06291874
Arm Type
Experimental
Arm Title
Treatment C- PF-06291874
Arm Type
Experimental
Arm Title
Treatment D- PF-06291874
Arm Type
Experimental
Arm Title
Treatment E- PF-06291874
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Tablet, once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
PF-06291874
Intervention Description
Tablet, 15 mg, once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
PF-06291874
Intervention Description
Tablet, 35 mg, once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
PF-06291874
Intervention Description
Tablet, 75 mg, once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
PF-06291874
Intervention Description
Tablet, 150 mg, once daily for 28 days
Primary Outcome Measure Information:
Title
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), or Serious Adverse Events (SAEs), or Hypoglycemic Adverse Events (HAE) or Withdrawals Due to Adverse Events (AEs)
Description
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. An HAE was identified by characteristic symptoms or blood glucose levels. TEAEs are events between first dose of study drug and up to 10-14 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.
Time Frame
Baseline up to 10-14 days after last dose of study drug, up to 42 days
Title
Number of Participants With Laboratory Test Abnormalities
Description
The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.
Time Frame
Baseline up to 10-14 days after last dose of study drug, up to 42 days
Title
Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Criteria of Potential Clinical Concern
Description
Vital Signs included seated supine systolic and diastolic blood pressure (BP) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic (SBP) greater than or equal to (>=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (<) 90 mm Hg; diastolic BP (DBP) >=20 mm Hg change from baseline, diastolic <50 mm Hg; 2), pulse rate <40 or greater than (>) 120 beats per minute (bpm).
Time Frame
Baseline up to 10-14 days after last dose of study drug, up to 42 days
Title
Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern
Description
ECG criteria of potential clinical concern were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): >=140 msec; >=50% increase from baseline; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): >=300 milliseconds (msec); >=25 percent (%) increase when baseline >200 msec; or increase >=50% when baseline less than or equal to (<=)200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value >=450 - <480 msec, >=480-<500 msec, >=500 msec; increase from baseline >=30 - <60, >=60 msec.
Time Frame
Baseline up to 10-14 days after last dose of study drug, up to 42 days
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Daily Glucose
Description
The mean daily glucose was determined from the area under the concentration (AUC) of the glucose concentrations measured at nominal times 0, 0.5, 1, 1.5, 2, 4, 6, 10, 12, 15 and 24 hours post dose. Mean daily glucose change from baseline (defined as Day 0) on Day 28.
Time Frame
Baseline and Day 28
Title
Change From Baseline in Fasting Plasma Glucose
Description
Fasting plasma glucose response change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Time Frame
Baseline, Day 14 and the mean of Days 28 and 29
Title
Percent Change From Baseline in Triglycerides
Description
Triglycerides percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Time Frame
Baseline, Day 14 and the mean of Days 28 and 29
Title
Percent Change From Baseline in Total Cholesterol
Description
Total cholesterol percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Time Frame
Baseline, Day 14 and the mean of Days 28 and 29
Title
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)
Description
LDL-C percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Time Frame
Baseline, Day 14 and the mean of Days 28 and 29
Title
Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)
Description
HDL-C percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Time Frame
Baseline, Day 14 and the mean of Days 28 and 29
Title
Percent Change From Baseline in Non-HDL-C
Description
Non-HDL-C percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 14, and the mean of Days 28 and 29.
Time Frame
Baseline, Day 14 and the mean of Days 28 and 29
Title
Percent Change From Baseline in Oxidized LDL
Description
Oxidized LDL percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Large LDL Particles
Description
Large LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Medium Small LDL Particles
Description
Medium small LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Small LDL Particles
Description
Small LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Very Small LDL Particles
Description
Very small LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Total LDL Particles
Description
Total LDL particles percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in LDL Size
Description
The LDL size percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (the mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Apolipoprotein B100
Description
The Apolipoprotein B100 was calculated as the difference between total Apolipoprotein B and Apolipoprotein B48 and analyzed the percent change from baseline (defined as mean of Day 0 and Day 1) on Day 28 (mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Percent Change From Baseline in Lipoprotein A
Description
The Lipoprotein A percent change from baseline (defined as the mean of Day 0 and Day 1 pre-dose) on Day 28 (mean of Days 28 and 29).
Time Frame
Baseline and the mean of Days 28 and 29
Title
Maximum Plasma Concentration (Cmax)
Description
Maximum PF-06291874 plasma concentration.
Time Frame
Day 28 (samples taken at 0, 2, 4, 8 and 24 hours after Day 28 dose)
Title
Time to Reach Cmax (Tmax)
Description
Time to maximum PF-06291874 plasma concentration.
Time Frame
Day 28 (samples taken at 0, 2, 4, 8 and 24 hours after Day 28 dose)
Title
Area Under the Concentration-Time Profile From Zero to Time Tau (AUCtau) (Where Tau=24 Hours)
Description
Area under the PF-06291874 plasma concentration-time profile from time zero to time tau, the dosing interval, where tau=24 hours.
Time Frame
Day 28 (samples taken at 0, 2, 4, 8 and 24 hours after Day 28 dose)
Title
Minimum Plasma Concentration (Cmin)
Description
Minimum PF-06291874 plasma concentration.
Time Frame
Day 28 (samples taken at 0, 2, 4, 8 and 24 hours after Day 28 dose)
Title
Apparent Clearance (CL/F)
Description
Apparent oral clearance of PF-06291874.
Time Frame
Day 28 (samples taken at 0, 2, 4, 8 and 24 hours after Day 28 dose)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male subjects and non-childbearing potential female subjects between the ages of 18 and 70 years old.
Body Mass Index of 18.0 to 45.4 kg/m2; and a total body weight of >50 kg
HbA1c value at the screening visit meeting once of the following criteria:
Currently taking acceptable oral antiglycemic drug therapy within 6.5 to 9.5%
Not currently taking any oral antiglycemic drug therapy within 7 to 10.5%
Fasting plasma glucose concentrations<270mg/dL at the screening and run-in visit, confirmed by a single repeat, if deemed necessary.
Subjects must be willing and able to perform self-tests of blood glucose at least 4 times per day, and maintain a diary for the duration of participation in the study; and therefore, subjects must be literate.
Exclusion Criteria:
History of Type 1 diabetes mellitus or secondary forms of diabetes
One or more self-reported hypoglycemic episodes of sever intensity within 3 months of screening; or 2 or more self-reported hypoglycemic episodes of severe intensity within the previous 6 months.
History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class II-IV heart failure, or transient ischemic attach within 6 months of screening.
History or evidence of diabetic complications with significant end organ damage, such as
Proliferative retinopathy and/or macular edema;
Diabetic neuropathy complicated by neuropathic ulcers;
Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure >100 mm Hg after at least a 5 minute seated rest. If the blood pressure exceeds this limit, the blood pressure may be repeated 2 more times following approximately 2 minutes of rest between measurements and the median of the 3 values should be used to determine subject eligibility;
Male subjects with partners currently pregnant; or male subjects capable of conceiving children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Anaheim Clinical Trials, LLC
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Profil Institute for Clinical Research, Inc.
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
Facility Name
Diablo Clinical Research, Inc.
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Avail Clinical Research, LLC
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
SeaView Research, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33125
Country
United States
Facility Name
SeaView Research, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33126
Country
United States
Facility Name
Compass Research, LLC
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Miami Research Associates, Inc.
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
MRA Clinical Research, LLC
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
MRA Clinical Research
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
Louisville Metabolic and Atherosclerosis Research Center
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40213
Country
United States
Facility Name
DaVita Clinical Research
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
Facility Name
Clinilabs, Inc.
City
Eatontown
State/Province
New Jersey
ZIP/Postal Code
07724
Country
United States
Facility Name
PRA International
City
Marlton
State/Province
New Jersey
ZIP/Postal Code
08053
Country
United States
Facility Name
Buffalo Clinical Research Center, LLC
City
Buffalo
State/Province
New York
ZIP/Postal Code
14202
Country
United States
Facility Name
High Point Clinical Trials Center, LLC
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27265
Country
United States
Facility Name
Community Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45255
Country
United States
Facility Name
Clinical Trials of Texas, Inc.
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Rainier Clinical Research Center, Inc.
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
12. IPD Sharing Statement
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4801011&StudyName=Safety%2C%20Tolerability%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Study%20Of%20PF-06291874%20As%20Oral%20Monotherapy%20To%20Treat%20Adults%20With%20Type%202%20Diabete
Description
To obtain contact information for a study center near you, click here.
Learn more about this trial
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs